Evolving Treatment Options in PsO

Welcome back to another HCPLive Peer Exchange series. In this episode titled, ‘Evolving Treatment Options in PsO,’ the panel of experts reviews how the plaque psoriasis treatment landscape has evolved and where topical, biologic, and oral systemic therapies fit within current care. The faculty describe the substantial gains achieved with biologic therapies, which have raised expectations for achieving clear or almost-clear skin in patients with moderate-to-severe disease. They also discuss advances in nonsteroidal topical therapies and their continued role for patients with limited disease as well as adjunctive use alongside systemic treatment.

The conversation then turns to a historically important gap in the oral treatment space. The panel explains that earlier oral options did not always provide the combination of efficacy, tolerability, and safety clinicians had come to expect from newer biologic therapies. With the emergence of newer targeted oral agents, however, clinicians now have additional systemic options for patients who may prefer a pill or who are taking the first step beyond topical treatment. Faculty discuss how they integrate these different approaches in practice and emphasize that treatment choice depends on disease burden, high-impact involvement, prior topical response, and individual patient needs.

In the next episode, ‘Redefining Treatment Goals and Patient Expectations in PsO,’ panelists will continue their discussion on plaque psoriasis and highlight how expectations have progressed from partial improvement toward complete clearance and outcomes that matter most to patients.